Antibody-drug conjugates: paving the future of oncology clinical development
European Pharmaceutical Review
OCTOBER 26, 2023
Antibody-drug conjugates (ADCs), such as datopotamab deruxtecan (Dato-DXd) and trastuzumab deruxtecan, have demonstrated compelling evidence of efficacy in oncology across numerous diseases in recent months.
Let's personalize your content